Gynaecology

Product Candidate Proprietary Platform Indication Discovery Pre‑Clinical Phase I Phase II/III Years IP Prevalence
DB19 Oral Syrup Oral DB Preterm Birth Prevention
14 0.5 (US)
15 (GL)